Arnold J. Levine | |
---|---|
8thPresident of Rockefeller University | |
In office 1998–2002 | |
Preceded by | Torsten Wiesel |
Succeeded by | Paul Nurse |
Personal details | |
Born | July 30,1939 85) Brooklyn,New York | (age
Nationality | American |
Alma mater | Binghamton University University of Pennsylvania California Institute of Technology |
Known for | p53 tumor suppressor protein |
Awards | Ciba-Drew Award (1995) Paul Ehrlich and Ludwig Darmstaedter Prize (1998) Louisa Gross Horwitz Prize for Biology or Biochemistry (1998) Charles S. Mott Prize (1999) Keio Medical Science Prize (2000) Albany Medical Center Prize in Medicine and Biomedical Research (2001) |
Scientific career | |
Fields | Molecular biology/Molecular virology/Molecular genetics |
Institutions | Institute for Advanced Study |
Thesis | A study of the role of adenovirus structural proteins in the cessation of host cell biosynthetic functions (1966) |
Doctoral advisor | Harold S. Ginsberg |
Arnold Jay Levine (born 1939) is an American molecular biologist. He was awarded the 1998 Louisa Gross Horwitz Prize for Biology or Biochemistry and was the first recipient of the Albany Medical Center Prize in Medicine and Biomedical Research in 2001 for his discovery of the tumor suppressor protein p53. [1]
He is currently Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton,New Jersey. [2]
Levine received his Ph.D. from the University of Pennsylvania in 1966. [3]
Levine discovered,with several colleagues,the p53 tumor suppressor gene in 1979,a protein involved in cell cycle regulation,and one of the most frequently mutated genes in human cancer,in work done as a professor in the biochemistry department at Princeton University. In 1979 Levine moved to become chairman of the department of microbiology at Stony Brook School of Medicine before moving back to Princeton in 1984.
In 1998 Levine became the Robert and Harriet Heilbrunn Professor of Cancer Biology and president of Rockefeller University. [4] In 2002,Levine resigned the presidency following allegations that he had an inappropriate sexual encounter with a female graduate student,while both were intoxicated. According to the woman involved,the encounter was consensual and blown out of proportion. [5] [6]
In 2002 he was appointed professor at The Cancer Institute of New Jersey in New Brunswick,New Jersey,then a part of the Robert Wood Johnson Medical School. Simultaneous to this appointment,in 2003,Levine became a visiting professor,then professor,in the newly created Simons Center for Systems Biology at the Institute for Advanced Study (IAS) in Princeton,New Jersey,where he has remained since. [7]
In 2017,Levine,with collaborators Benjamin Greenbaum,and Marta Luksza,developed the first mathematical model for predicting patient response to immunotherapy. [8] Their recent work extends to studying immune resistance mechanisms and patterns of evolution. [9]
In addition to the Louisa Gross Horwitz Prize (Columbia University) (1998) and the inaugural Albany Medical Center Prize in 2001,Levine has received numerous awards and honors. He was elected a Member of the U.S. National Academy of Sciences in 1991, [10] a Member of the Institute of Medicine in 1995, [4] and a member of the American Philosophical Society in 2000. [11] He won the Ciba-Drew Award in 1995. The importance of p53 in cancer biology led to a number of cancer-related awards,including the Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research (1994),the Charles S. Mott Prize from the General Motors Cancer Research Foundation (1999),the Keio Medical Science Prize (2000), [12] the Memorial Sloan-Kettering Cancer Center's Medal for Outstanding Contributions to Biomedical Research (2000),the Albany Medical Center Prize in Medicine and Biomedical Research (2001),the Dart/NYU Biotechnology Achievement Award in Basic Biotechnology (2008);the American Association for Cancer Research's Kirk A. Landon–AACR Prize for Basic Cancer Research (2008),the American Cancer Society's Medal of Honor (2009),and the Lars Onsager Medal (2012). [13]
The Rockefeller University is a private biomedical research and graduate-only university in New York City, New York. It focuses primarily on the biological and medical sciences and provides doctoral and postdoctoral education. It is classified as a "Special Focus – Research Institution". Rockefeller is the oldest biomedical research institute in the United States.
Elizabeth Helen Blackburn is an Australian-American Nobel laureate who is the former president of the Salk Institute for Biological Studies. In 1984, Blackburn co-discovered telomerase, the enzyme that replenishes the telomere, with Carol W. Greider. For this work, she was awarded the 2009 Nobel Prize in Physiology or Medicine, sharing it with Carol W. Greider and Jack W. Szostak, becoming the first Australian woman Nobel laureate.
Ronald Mark Evans is an American Biologist, Professor and Head of the Salk’s Gene Expression Laboratory, and the March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute for Biological Studies in La Jolla, California and a Howard Hughes Medical Institute Investigator. Dr. Ronald M. Evans is known for his original discoveries of nuclear hormone receptors (NR), a special class of transcriptional factor, and the elucidation of their universal mechanism of action, a process that governs how lipophilic hormones and drugs regulate virtually every developmental and metabolic pathway in animals and humans. Nowadays, NRs are among the most widely investigated group of pharmaceutical targets in the world, already yielding benefits in drug discovery for cancer, muscular dystrophies, osteoporosis, type II diabetes, obesity, and cardiovascular diseases. His current research focuses on the function of nuclear hormone signaling and their function in metabolism and cancer.
Robert G. Roeder is an American biochemist. He is known as a pioneer scientist in eukaryotic transcription. He discovered three distinct nuclear RNA polymerases in 1969 and characterized many proteins involved in the regulation of transcription, including basic transcription factors and the first mammalian gene-specific activator over five decades of research. He is the recipient of the Gairdner Foundation International Award in 2000, the Albert Lasker Award for Basic Medical Research in 2003, and the Kyoto Prize in 2021. He currently serves as Arnold and Mabel Beckman Professor and Head of the Laboratory of Biochemical and Molecular Biology at The Rockefeller University.
Bert Vogelstein is director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center. A pioneer in the field of cancer genomics, his studies on colorectal cancers revealed that they result from the sequential accumulation of mutations in oncogenes and tumor suppressor genes. These studies now form the paradigm for modern cancer research and provided the basis for the notion of the somatic evolution of cancer.
Thomas Eugene Shenk is an American virologist. He is currently Emeritus Professor of Life Sciences in the Department of Molecular Biology at Princeton University.
Charles David Allis was an American molecular biologist, and the Joy and Jack Fishman Professor at the Rockefeller University. He was also the Head of the Laboratory of Chromatin Biology and Epigenetics, and a professor at the Tri-Institutional MD–PhD Program.
Steven A. Rosenberg is an American cancer researcher and surgeon, chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He pioneered the development of immunotherapy that has resulted in the first effective immunotherapies and the development of gene therapy. He is the first researcher to successfully insert foreign genes into humans.
Philippa "Pippa" Marrack, FRS is an English immunologist and academic, based in the United States, best known for her research and discoveries pertaining to T cells. Marrack is the Ida and Cecil Green Professor and chair of the Department of Biomedical Research at National Jewish Health and a distinguished professor of immunology and microbiology at the University of Colorado Denver.
Victor R. Ambros is an American developmental biologist and Nobel Laureate who discovered the first known microRNA (miRNA). He is a professor at the University of Massachusetts Medical School. He completed both his undergraduate and doctoral studies at the Massachusetts Institute of Technology. Ambros received the Nobel Prize in Physiology or Medicine in 2024 for his research on microRNA.
The Wiley Prize in Biomedical Sciences is intended to recognize breakthrough research in pure or applied life science research that is distinguished by its excellence, originality and impact on our understanding of biological systems and processes. The award may recognize a specific contribution or series of contributions that demonstrate the nominee's significant leadership in the development of research concepts or their clinical application. Particular emphasis will be placed on research that champions novel approaches and challenges accepted thinking in the biomedical sciences.
Brian J. Druker, M.D. is a physician-scientist at Oregon Health & Science University (OHSU), in Portland, Oregon. He is the chief executive officer of OHSU's Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.
Aviv Regev is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member at the Broad Institute of MIT and Harvard and professor at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas. Allison is Regental Professor and Founding-Director of James P. Allison Institute at the MD Anderson Cancer Center.
George C. Prendergast is an American biomedical scientist. His research has focused on cancer pathobiology and immunology. Since 2004, he has been the president and CEO of Lankenau Institute for Medical Research, a cancer-focused research center in the U.S. He is also the co-director of the Program in Cancer Cell Biology & Signaling at the Sidney Kimmel Cancer Center, Thomas Jefferson University.
Anthony Rex Hunter is a British-American biologist who is a professor of biology at the Salk Institute for Biological Studies and the University of California San Diego. His research publications list his name as Tony Hunter.
Institute for Medical Research, Israel-Canada (IMRIC) is a research institute affiliated with the Faculty of Medicine of the Hebrew University of Jerusalem.
Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.
Guillermina 'Gigi' Lozano is an American geneticist. She is a Professor and Hubert L. Olive Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer at the University of Texas MD Anderson Cancer Center, Houston, Texas. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression and that is disturbed in many cancers. She was the first to recognize that the p53 gene encoded a transcriptional activator of other genes Her lab has made significant contributions by developing and analyzing mouse models to study the activities of mutant p53, revealing how these mutations drive tumor development and progression. She also found out how the Mdm2 and Mdm4 proteins work in the body, especially in stopping cancer and controlling p53. This research suggested that blocking Mdm2/4 could be a new way to treat cancer.
Eileen White is an American professor and scientist who currently serves as deputy director, chief scientific officer, and associate director for basic science at the Rutgers Cancer Institute of New Jersey. She is also the distinguished professor of molecular biology and biochemistry at Rutgers University. White was elected member of the National Academy of Sciences in 2021.